Chengdu Easton Biopharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688513.SS

Chengdu Easton Biopharmaceuticals Co., Ltd. Market Capitalization on January 14, 2025: USD 719.75 M

Chengdu Easton Biopharmaceuticals Co., Ltd. Market Capitalization is USD 719.75 M on January 14, 2025, a -23.77% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Chengdu Easton Biopharmaceuticals Co., Ltd. 52-week high Market Capitalization is USD 1.06 B on October 08, 2024, which is 46.92% above the current Market Capitalization.
Chengdu Easton Biopharmaceuticals Co., Ltd. 52-week low Market Capitalization is USD 693.40 M on July 30, 2024, which is -3.66% below the current Market Capitalization.
Chengdu Easton Biopharmaceuticals Co., Ltd. average Market Capitalization for the last 52 weeks is USD 862.89 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Shanghai Stock Exchange: 688513.SS

Chengdu Easton Biopharmaceuticals Co., Ltd.

CEO	Mr. Mingxu Yuan
IPO Date	Sept. 2, 2020
Location	China
Headquarters	No.8, Xiyuan Avenue
Employees	1,400
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry , and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.

Key trends

Past 5 years